Haris Zahoor

Title(s)Assistant Professor of Clinical Medicine
SchoolKeck School of Medicine of USC
vCardDownload vCard

    Collapse Bibliographic 
    Collapse Publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help.
    List All   |   Timeline
    1. Selvakumar GP, Ahmed ME, Raikwar SP, Thangavel R, Kempuraj D, Dubova I, Saeed D, Zahoor H, Premkumar K, Zaheer S, Iyer S, Zaheer A. CRISPR/Cas9 Editing of Glia Maturation Factor Regulates Mitochondrial Dynamics by Attenuation of the NRF2/HO-1 Dependent Ferritin Activation in Glial Cells. J Neuroimmune Pharmacol. 2019 Feb 27. PMID: 30810907.
      View in: PubMed
    2. Zahoor H, Grivas P. The Cancer Immunogram: A Pledge for a Comprehensive Biomarker Approach for Personalized Immunotherapy in Urothelial Cancer. Eur Urol. 2019 Mar; 75(3):445-447. PMID: 30558899.
      View in: PubMed
    3. Zahoor H, Barata PC, Jia X, Martin A, Allman KD, Wood LS, Gilligan TD, Grivas P, Ornstein MC, Garcia JA, Rini BI. Patterns, predictors and subsequent outcomes of disease progression in metastatic renal cell carcinoma patients treated with nivolumab. J Immunother Cancer. 2018 Oct 17; 6(1):107. PMID: 30333065.
      View in: PubMed
    4. Zahoor H, Pavicic PG, Przybycin C, Ko J, Stephens L, Radivoyevitch T, Jia X, Diaz-Montero CM, Finke J, Rayman PA, Gilligan TD, Grivas P, Ornstein M, Garcia JA, Rini BI. Evaluation of T cell infiltration in matched biopsy and nephrectomy samples in renal cell carcinoma. Medicine (Baltimore). 2018 Sep; 97(37):e12344. PMID: 30212988.
      View in: PubMed
    5. Kempuraj D, Thangavel R, Selvakumar GP, Ahmed ME, Zaheer S, Raikwar SP, Zahoor H, Saeed D, Dubova I, Giler G, Herr S, Iyer SS, Zaheer A. Mast Cell Proteases Activate Astrocytes and Glia-Neurons and Release Interleukin-33 by Activating p38 and ERK1/2 MAPKs and NF-?B. Mol Neurobiol. 2018 Jun 18. PMID: 29916143.
      View in: PubMed
    6. Koshkin VS, Barata PC, Rybicki LA, Zahoor H, Almassi N, Redden AM, Fergany AF, Kaouk J, Haber GP, Stephenson AJ, Ornstein MC, Gilligan T, Garcia JA, Rini BI, Grivas P. Feasibility of Cisplatin-Based Neoadjuvant Chemotherapy in Muscle-Invasive Bladder Cancer Patients With Diminished Renal Function. Clin Genitourin Cancer. 2018 08; 16(4):e879-e892. PMID: 29576445.
      View in: PubMed
    7. Zahoor H, Rini BI, Ornstein MC. Extended therapy breaks from VEGFR TKI therapy in renal cell carcinoma: Sometimes less is more. Oncotarget. 2018 Mar 06; 9(18):14036-14037. PMID: 29581822.
      View in: PubMed
    8. Zahoor H, Elson P, Stephenson A, Haber GP, Kaouk J, Fergany A, Lee B, Koshkin V, Ornstein M, Gilligan T, Garcia JA, Rini B, Grivas P. Patient Characteristics, Treatment Patterns and Prognostic Factors in Squamous Cell Bladder Cancer. Clin Genitourin Cancer. 2018 04; 16(2):e437-e442. PMID: 29154041.
      View in: PubMed
    9. Kempuraj D, Thangavel R, Selvakumar GP, Zaheer S, Ahmed ME, Raikwar SP, Zahoor H, Saeed D, Natteru PA, Iyer S, Zaheer A. Brain and Peripheral Atypical Inflammatory Mediators Potentiate Neuroinflammation and Neurodegeneration. Front Cell Neurosci. 2017; 11:216. PMID: 28790893.
      View in: PubMed
    10. Zahoor H, Rini BI. Emerging growth factor receptor antagonists for the treatment of renal cell carcinoma. Expert Opin Emerg Drugs. 2016 Dec; 21(4):431-440. PMID: 27690664.
      View in: PubMed
    11. Tarhini AA, Zahoor H, Yearley JH, Gibson C, Rahman Z, Dubner R, Rao UN, Sander C, Kirkwood JM. Tumor associated PD-L1 expression pattern in microscopically tumor positive sentinel lymph nodes in patients with melanoma. J Transl Med. 2015 Sep 30; 13:319. PMID: 26419843; PMCID: PMC4589168.
    12. Tarhini AA, Zahoor H, Lin Y, Malhotra U, Sander C, Butterfield LH, Kirkwood JM. Baseline circulating IL-17 predicts toxicity while TGF-ß1 and IL-10 are prognostic of relapse in ipilimumab neoadjuvant therapy of melanoma. J Immunother Cancer. 2015; 3:39. PMID: 26380086; PMCID: PMC4570556.
    13. Tarhini AA, Lin Y, Zahoor H, Shuai Y, Butterfield LH, Ringquist S, Gogas H, Sander C, Lee S, Agarwala SS, Kirwood JM. Pro-Inflammatory Cytokines Predict Relapse-Free Survival after One Month of Interferon-a but Not Observation in Intermediate Risk Melanoma Patients. PLoS One. 2015; 10(7):e0132745. PMID: 26192408; PMCID: PMC4508028.
    14. Zahoor H, Luketich JD, Weksler B, Winger DG, Christie NA, Levy RM, Gibson MK, Davison JM, Nason KS. The revised American Joint Committee on Cancer staging system (7th edition) improves prognostic stratification after minimally invasive esophagectomy for esophagogastric adenocarcinoma. Am J Surg. 2015 Oct; 210(4):610-7. PMID: 26188709; PMCID: PMC4575853 [Available on 10/01/16].
    15. Zahoor H, Luketich JD, Levy RM, Awais O, Winger DG, Gibson MK, Nason KS. A propensity-matched analysis comparing survival after primary minimally invasive esophagectomy followed by adjuvant therapy to neoadjuvant therapy for esophagogastric adenocarcinoma. J Thorac Cardiovasc Surg. 2015 Feb; 149(2):538-47. PMID: 25454907; PMCID: PMC4492295.
    16. Tarhini AA, Zahoor H, McLaughlin B, Gooding WE, Schmitz JC, Siegfried JM, Socinski MA, Argiris A. Phase I trial of carboplatin and etoposide in combination with panobinostat in patients with lung cancer. Anticancer Res. 2013 Oct; 33(10):4475-81. PMID: 24123018; PMCID: PMC4157617.
    17. Zaidi AH, Komatsu Y, Kelly LA, Malhotra U, Rotoloni C, Kosovec JE, Zahoor H, Makielski R, Bhatt A, Hoppo T, Jobe BA. Smoothened inhibition leads to decreased proliferation and induces apoptosis in esophageal adenocarcinoma cells. Cancer Invest. 2013 Aug; 31(7):480-9. PMID: 23915072.
      View in: PubMed